Source comparison
Is PT-141 Safe According to Studies? (Full Comparison)
Nausea incidence 40% of subjects (transient, self-limiting within 6 hours) Placebo: 1%; GLP-1 agonists: 30–50% sustained Manageable with prophylactic ondansetron; does not produce tolerance or worsen over time Blood pressure elevation Mean +3–5mmHg systolic fo
This comparison does not assign a generated winner or score.
- Nausea incidence
- 40% of subjects (transient, self-limiting within 6 hours)
- Placebo: 1%; GLP-1 agonists: 30–50% sustained
- Manageable with prophylactic ondansetron; does not produce tolerance or worsen over time
- Blood pressure elevation
- Mean +3–5mmHg systolic for 8–12 hours post-dose
- Placebo: no change; pseudoephedrine: +10–15mmHg sustained
- Transient and dose-dependent; no cumulative effect observed in 52-week studies; contraindicated in uncontrolled hypertension
- Injection site reactions
- 13% (mild erythema, rarely lasting >24 hours)
- Subcutaneous peptides generally: 10–20%
- Expected for subcutaneous administration; proper technique reduces incidence
- Serious adverse events
- <4% discontinuation rate; no deaths, MIs, or strokes
- FDA approval threshold: <5% serious AE rate
- Acceptable safety margin for an elective-use medication treating quality-of-life condition
- Long-term tolerability
- Adverse event rates stable across 52 weeks of intermittent use
- Most peptides show tolerance development or worsening AE profile over time
- Unusual stability; suggests lack of receptor desensitisation or organ toxicity